Figure 2.

TPF and cinobufotalin suppress the viability of UMSCC5 and FADU cells time-dependently.

Notes: (A) FADU and (B) UMSCC5 cells were treated by IC₅₀ concentrations of TPF alone, IC₅₀ concentrations of cinobufotalin alone, IC₅₀ concentration of cinobufotalin with IC₅₀ concentration of TPF, or half IC₅₀ concentration of cinobufotalin with half IC₅₀ concentration of TPF for 1, 2, and 3 days, then were detected by CCK-8 kit for the viability alterations, with no medicine treatment as control, and proliferation curves were drawn according to the variation of the absorbance.

Abbreviations: CCK-8, cell counting kit-8; TPF, a mixture comprising paclitaxel, cisplatin, and 5-fluorouracil.